The German bio-pharmaceuticals company MEDIGENE AG bought, for EUR 55 million, the 91% of the capital in the American bio-technology company, which it did not already hold. It had already acquired on the stock market 9% of the capital last year. Thanks to this operation MEDIGENE could increase its annual turnover to USD 1.5 billion against the present 500 million.